Breaking News
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
January 16, 2018 - Aztec apocalypse found to be Salmonella outbreak
January 16, 2018 - Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy
January 16, 2018 - Three Ineffective Institutional Approaches to Quality Improvement in Healthcare
January 16, 2018 - New technology accelerates autism diagnosis and treatment
January 16, 2018 - Preterm babies likely to experience delays in auditory brain development, study reveals
January 16, 2018 - Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis
January 16, 2018 - Mitochondrial impairment may actually protect the brain in Parkinson’s disease, study shows
January 15, 2018 - Energy drinks can have adverse health effects on youth, study reveals
January 15, 2018 - 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
January 15, 2018 - Wanted: ‘Breathalyzer’ for Cannabis Use
January 15, 2018 - Surfers more likely to get antibiotic resistant E. coli in their guts
January 15, 2018 - “Baby brain” a real clinical entity finds study
January 15, 2018 - Whole of Britain to be put on a diet plan come March
January 15, 2018 - Neighborhood Deprivation Linked to Heart Failure
January 15, 2018 - Omega-3 and Omega-6 fatty acid intake may affect lupus outcomes
January 15, 2018 - Scientists discover new enzyme that could reduce obesity rates
January 15, 2018 - Evidence suggests two patterns of early symptoms precede and predict later BD risk
January 15, 2018 - Harm minimization approach for smoking cessation with e-cigarettes
January 15, 2018 - Surgery or Antibiotics for Appendicitis? Here’s What Patients Chose
January 15, 2018 - ASH: Frailty Screening Tool Guides Therapy in Elderly
January 15, 2018 - Study shows video games could cut dementia risk in seniors
January 15, 2018 - Common Food Additive Promoting C. diff?
January 15, 2018 - Mild traumatic brain injury causes long-term damage in mice
January 15, 2018 - Circadian clock proteins set the pace of plant growth
January 15, 2018 - Two proteins shown to regenerate brain in Parkinson’s disease
January 15, 2018 - Jotting down tasks may ease falling asleep, study says
January 15, 2018 - Chi-Med Initiates Fruquintinib U.S. Clinical Trials
January 15, 2018 - Cell-Free DNA May Help Pinpoint Breast Ca Survival
January 15, 2018 - What goes on inside a medically supervised injection facility?
January 15, 2018 - Research provides new model to better ascertain HIV mortality rates in Zambia
January 15, 2018 - Genetic analysis can enhance outcomes of depression treatment
January 15, 2018 - Variations in bacterial strains can trigger varying immune responses, study states
January 15, 2018 - TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
January 15, 2018 - HIV Vaccine Shows ‘Positive Signal’ in Small Study
January 15, 2018 - Researchers demonstrate RAS dimers are essential for cancer
January 15, 2018 - Groundbreaking report highlights plan to end bowel cancer
January 15, 2018 - Doc Aspires to Bring ‘Medicine the Musical’ to Off-Broadway
January 15, 2018 - Does an exploding brain network cause chronic pain?
January 15, 2018 - Researchers use novel PET tracer to assess myelin damage in mouse models of MS
January 15, 2018 - Survival strategy of mRNAs during sugar deficiency in the cell
January 15, 2018 - Hormone Therapy May Ease Depression Linked to Menopause
January 15, 2018 - Pain Sensitization Declines After Bariatric Tx in Obese Patients
January 15, 2018 - C7 nerve transfer improves function in spastic arm paralysis
January 15, 2018 - Australian kids are drinking and smoking far less than before
January 15, 2018 - Worsening of anxiety symptoms may be early indicator of Alzheimer’s disease
January 15, 2018 - Early testing for influenza symptoms can limit severe, life-threatening disease
January 15, 2018 - Exposure to estrogen-mimicking compounds may reverse effects of breast cancer treatment
January 15, 2018 - Lipids May Play Key Role in Abdominal Aneurysm
January 15, 2018 - Raw Dough’s a Raw Deal and Could Make You Sick
January 15, 2018 - Thinking about germs makes people concerned about how they look
January 15, 2018 - Pitt scientists develop new guidelines to alleviate EMS personnel fatigue
January 15, 2018 - Discovery suggests new approach for targeting most-wanted molecular culprits in cancer
January 14, 2018 - Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-Cell Lymphoma (PTCL)
January 14, 2018 - Adding Enzyme to Chemo Combo Improves Outcomes in Pancreatic CA
January 14, 2018 - Research suggests ways to help mentally ill in Ghana’s prayer camps
January 14, 2018 - U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer
January 14, 2018 - Availability of qualified nurses in hospitals affects patient satisfaction
January 14, 2018 - Prostate cancer’s gene-determined ‘immune landscape’ dictates tumor progression
January 14, 2018 - Online CME: Is This Your First Choice?
PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA

PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA

image_pdfDownload PDFimage_print
Treatment for Duchenne Muscular Dystrophy

PTC Therapeutics Receives Complete Response Letter for Ataluren’s NDA

SOUTH PLAINFIELD, N.J., Oct. 25, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of Drug Evaluation I of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) of the investigational medicine ataluren for the treatment of nonsense mutation dystrophinopathies.

“We are extremely disappointed for the Duchenne community and strongly disagree with the agency’s conclusions,” said Stuart W. Peltz, Ph.D., chief executive officer of PTC Therapeutics. “We believe that this decision fails to consider the benefit-risk of ataluren and the high unmet medical need. Therefore, we plan to file a formal dispute resolution request next week.”

The letter from the Office of Drug Evaluation I of the FDA stated that it is unable to approve the application in its current form. Specifically, the letter indicated that evidence of effectiveness from an additional adequate and well-controlled clinical trial(s) will be necessary at a minimum to provide substantial evidence of effectiveness. The letter also mentioned other nonclinical and CMC matters that PTC is in the process of addressing.

About ataluren (Translarna™)

Ataluren, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna, tradename of ataluren, is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Ataluren is an investigational new drug in the United States.

About Duchenne Muscular Dystrophy

Primarily affecting males, Duchenne muscular dystrophy (DMD) is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with DMD can lose the ability to walk as early as age ten, followed by loss of the use of their arms. DMD patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties. It is estimated that a nonsense mutation is the cause of DMD in approximately 13 percent of patients.

About PTC Therapeutics

PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in RNA biology. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. Since its founding nearly 20 years ago, PTC’s mission has focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey. For more information on the company, please visit our website www.ptcbio.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release are forward-looking statements, including statements regarding the future expectations, plans and prospects for PTC; PTC’s plans for further interactions with the FDA; the outcome of any formal dispute resolution request; the clinical utility and potential advantages of Translarna (ataluren); PTC’s strategy, future operations, future financial position, future revenues or projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “look forward”, “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including PTC’s ability to resolve the matters set forth in the Complete Response letter it received from the FDA in connection with its NDA for Translarna for the treatment of nmDMD either via outcome of any formal dispute resolution request or other interactions with the FDA, and PTC’s ability to perform additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC’s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area, including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC’s ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open label extension; the eligible patient base and commercial potential of Translarna and PTC’s other product candidates; PTC’s ability to commercialize and commercially manufacture Translarna in general and specifically as a treatment for nmDMD; the outcome of pricing and reimbursement negotiations in those territories in which PTC is authorized to sell Translarna for the treatment of nmDMD; the outcome of ongoing or future clinical studies in Translarna; expectations for regulatory approvals; PTC’s ability to meet existing or future regulatory standards with respect to Translarna; and the factors discussed in the “Risk Factors” section of PTC’s most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

SOURCE PTC Therapeutics, Inc.

Posted: October 2017

Related Articles

Translarna (ataluren) FDA Approval History

Tagged with:

About author

Related Articles